medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2007, Número 07-08

<< Anterior Siguiente >>

Medicina & Laboratorio 2007; 13 (07-08)


Proteinuria

Vanegas AN, Arbeláez GM

Idioma: Español
Referencias bibliográficas: 76
Paginas: 327-344
Archivo PDF: 1937.34 Kb.


RESUMEN

La proteinuria describe una condición en la cual la orina contiene una cantidad aumentada de proteínas. Es un hallazgo relativamente frecuente en los adultos en consulta externa que se presenta por una alteración en la barrera de filtración glomerular que deja escapar las proteínas hacia la orina. La proteinuria puede ser una manifestación de una enfermedad renal crónica como de una causa benigna como la fiebre, el ejercicio intenso, la deshidratación y algunas enfermedades agudas. La proteinuria se clasifica en tres categorías dependiendo del origen de la patología y de las proteínas excretadas en la orina: proteinuria glomerular, proteinuria tubular y proteinuria por sobreflujo. En el presente módulo se describen las principales causas de proteinuria, las enfermedades asociadas a esta entidad y los exámenes de laboratorio iniciales que permitan clasificar a los pacientes. Por último se presenta un algoritmo para la evaluación del paciente con esta condición.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Samuelsson O, Wilhelmsen L, Elmfeldt D, Pennert K, Wedel H, Wikstrand J, et al. Predictors of cardiovascular morbidity in treated hypertension: results from the primary preventive trial in Goteborg, Sweden. J Hypertens 1985; 3: 167-176.

  2. Adler SG FK. The patient with hematuria, proteinuria, or both, and abnormal findings on urinary microscopy. In Manual of Nephrology, S. RW.6a ed., 2005; Lippincott Williams & Wilkins, 126-130.

  3. Sedor JR SJ. Approach to the patient with proteinuria and nephrotic syndrome. In Kelley’s Textbook of Internal Medicine, D. H. Humes HD, Gardner LB, Griffin JW, Harris ED, Hazzard WR, King TE, Loriaux DL, Nabel EG, Todd RF, Traber PG.4a ed., 2000; Lippincot Williams & Wilkins, 1099-1104.

  4. Woolhandler S, Pels RJ, Bor DH, Himmelstein DU, Lawrence RS. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria. JAMA 1989; 262: 1214-1219.

  5. Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1992; 42: 960-966.

  6. Ghitescu L, Desjardins M, Bendayan M. Immunocytochemical study of glomerular permeability to anionic, neutral and cationic albumins. Kidney Int 1992; 42: 25-32.

  7. Larson TS. Evaluation of proteinuria. Mayo Clin Proc 1994; 69: 1154-1158.

  8. Guasch A, Deen WM, Myers BD. Charge selectivity of the glomerular filtration barrier in healthy and nephrotic humans. J Clin Invest 1993; 92: 2274-2282.

  9. Ahmed Z, Lee J. Asymptomatic urinary abnormalities. Hematuria and proteinuria. Med Clin North Am 1997; 81: 641-652.

  10. Farquhar MG. The glomerular basement membrane: not gone, just forgotten. J Clin Invest 2006; 116: 2090-2093.

  11. JS C. The patient with proteinuria and/or haematuria. In Oxford Textbook of Clinical Nephrology. C. J. Davison AM, Grunfeld JP, Ponticelli CR, Eberhard W, Christopher G, Ypersele C 3a ed., 2005; Oxford University Press, 390-408.

  12. Stone RA. Office evaluation of the patient with proteinuria. Postgrad Med 1989; 86: 241-244.

  13. NKF. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.

  14. Abuelo JG. Proteinuria: diagnostic principles and procedures. Ann Intern Med 1983; 98: 186-191.

  15. Longo D, Anderson KC. Plasma cell disorders. In Harrison´s Principles of Internal Medicine, Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. 16 ed., 2005; McGraw-Hill, New York. 656-662.

  16. Wagner MG, Smith FG, Jr., Tinglof BO, Jr., Cornberg E. Epidemiology of proteinuria. A study of 4,807 schoolchildren. J Pediatr 1968; 73: 825-832.

  17. Marks MI, McLaine PN, Drummond KN. Proteinuria in children with febrile illnesses. Arch Dis Child 1970; 45: 250-253.

  18. Jensen H, Henriksen K. Proteinuria in non-renal infectious diseases. Acta Med Scand 1974; 196: 75-82.

  19. Campanacci L, Faccini L, Englaro E, Rustia R, Guarnieri GF, Barat R, et al. Exercise-induced proteinuria. Contrib Nephrol 1981; 26: 31-41.

  20. Poortmans JR. Postexercise proteinuria in humans. Facts and mechanisms. Jama 1985; 253: 236-240.

  21. Albright R, Brensilver J, Cortell S. Proteinuria in congestive heart failure. Am J Nephrol 1983; 3: 272-275.

  22. Vehaskari VM, Rapola J. Isolated proteinuria: analysis of a school-age population. J Pediatr 1982; 101: 661-668.

  23. Springberg PD, Garrett LE, Jr., Thompson AL, Jr., Collins NF, Lordon RE, Robinson RR. Fixed and reproducible orthostatic proteinuria: results of a 20-year follow-up study. Ann Intern Med 1982; 97: 516-519.

  24. Robinson RR. Isolated proteinuria. Contrib Nephrol 1985; 48: 101-110.

  25. Sinniah R, Law CH, Pwee HS. Glomerular lesions in patients with asymptomatic persistent andorthostatic proteinuria discovered on routine medical examination. Clin Nephrol 1977; 7: 1-14.

  26. Gyure WL. Comparison of several methods for semiquantitative determination of urinary protein. Clin Chem 1977; 23: 876-879.

  27. Domachevsky L, Grupper M, Shochat T, Adir Y. Proteinuria on dipstick urine analysis after sexual intercourse. BJU Int 2006; 97: 146-148.

  28. Campuzano-Maya G, Arbeláez-Gómez M. Uroanálisis: más que un examen de rutina. Medicina & Laboratorio 2006; 12: 511-556.

  29. Hogg RJ. Adolescents with proteinuria and/or the nephrotic syndrome. Adolesc Med Clin 2005; 16: 163-172.

  30. Kashif W, Siddiqi N, Dincer AP, Dincer HE, Hirsch S. Proteinuria: how to evaluate an important finding. Cleve Clin J Med 2003; 70: 535-537, 541-534, 546-537.

  31. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360.

  32. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157: 1413-1418.

  33. Bog-Hansen E, Merlo J, Gullberg B, Melander A, Rastam L, Lindblad U. Survival in patients with hypertension treated in primary care. A population-based follow-up study in the Skaraborg Hypertension and Diabetes Project. Scand J Prim Health Care 2004; 22: 222-227.

  34. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992-1997.

  35. Romundstad S, Holmen J, Hallan H, Kvenild K, Kruger O, Midthjell K. Microalbuminuria, cardiovascular disease and risk factors in a nondiabetic/nonhypertensive population. The Nord-Trondelag Health Study (HUNT, 1995-97), Norway. J Intern Med 2002; 252: 164-172.

  36. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16: 1325-1333.

  37. Pontremoli R, Nicolella C, Viazzi F, Ravera M, Sofia A, Berruti V, et al. Microalbuminuria is an early marker of target organ damage in essential hypertension. Am J Hypertens 1998; 11: 430-438.

  38. Ljungman S, Wikstrand J, Hartford M, Berglund G. Urinary albumin excretion--a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens 1996; 9: 770-778.

  39. Gonzalez-Juanatey JR, Alegria E, Zamorano JL, Bertomeu V, Velasco O, Parrondo I, et al. Albuminuria and cardiovascular risk: basal results of the KORAL-CARDIO study. Nefrologia 2006; 26: 426-432.

  40. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. Jama 2001; 286: 421-426.

  41. Kvenild K, Romundstad S, Midthjell K, Kruger O, Hallan H, Holmen J. Microalbuminuria in treated hypertensives: only a mirror image of cardiovascular risk? The HUNT Study, Norway. Scand J Prim Health Care 2006; 24: 145-153.

  42. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14: 223-228.

  43. Ojogwu LI. Persistent proteinuria in asymptomatic individuals: renal biopsy studies. Trop Geogr Med 1985; 37: 69-73.

  44. Richards NT, Darby S, Howie AJ, Adu D, Michael J. Knowledge of renal histology alters patient management in over 40% of cases. Nephrol Dial Transplant 1994; 9: 1255-1259.

  45. Hlatky MA. Is renal biopsy necessary in adults with nephrotic syndrome. Lancet 1982; 2: 1264-1268.

  46. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468-1474.

  47. Daskalakis N, Winn MP. Focal and segmental glomerulosclerosis: varying biologic mechanisms underlie a final histopathologic end point. Semin Nephrol 2006; 26: 89-94.

  48. Daskalakis N, Winn MP. Focal and segmental glomerulosclerosis. Cell Mol Life Sci 2006; 63: 2506-2511.

  49. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004; 15: 2169-2177.

  50. Polkinghorne KR. Detection and measurement of urinary protein. Curr Opin Nephrol Hypertens 2006; 15: 625-630.

  51. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-1084.

  52. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281-287.

  53. Mathiesen ER, Oxenboll B, Johansen K, Svendsen PA, Deckert T. Incipient nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia 1984; 26: 406-410.

  54. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 311: 89-93.

  55. Lapuz MH. Diabetic nephropathy. Med Clin North Am 1997; 81: 679-688.

  56. Galla JH. IgA nephropathy. Kidney Int 1995; 47: 377-387.

  57. Lai KN, Wang AY. IgA nephropathy: common nephritis leading to end-stage renal failure. Int J Artif Organs 1994; 17: 457-460.

  58. Coppo R, D’Amico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005; 18: 503-512.

  59. Jennette JC, Falk RJ. Diagnosis and management of glomerular diseases. Med Clin North Am 1997; 81: 653-677.

  60. Gedalia A. Henoch-Schonlein purpura. Curr Rheumatol Rep 2004; 6: 195-202.

  61. Goldstein AR, White RH, Akuse R, Chantler C. Long-term follow-up of childhood Henoch-Schonlein nephritis. Lancet 1992; 339: 280-282.

  62. Lau KK, Wyatt RJ. Glomerulonephritis. Adolesc Med Clin 2005; 16: 67-85.

  63. Agrawal N, Chiang LK, Rifkin IR. Lupus nephritis. Semin Nephrol 2006; 26: 95-104.

  64. Adelman RD. Obesity and renal disease. Curr Opin Nephrol Hypertens 2002; 11: 331-335.

  65. Rutkowski P, Klassen A, Sebekova K, Bahner U, Heidland A. Renal disease in obesity: the need for greater attention. J Ren Nutr 2006; 16: 216-223.

  66. Lim AK. Nephrotic-range proteinuria in the obese patient. Med J Aust 2006; 185: 405-406.

  67. Bosma RJ, Krikken JA, Homan van der Heide JJ, de Jong PE, Navis GJ. Obesity and renal hemodynamics. Contrib Nephrol 2006; 151: 184-202.

  68. Vriesendorp R, Donker AJ, de Zeeuw D, de Jong PE, van der Hem GK, Brentjens JR. Effects of nonsteroidal anti-inflammatory drugs on proteinuria. Am J Med 1986; 81: 84-94.

  69. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007; 49: 12-26.

  70. Levitt JI. The prognostic significance of proteinuria in young college students. Ann Intern Med. 1967; 66: 685.

  71. Rosner MH, Bolton WK. Core Curriculum in Nephrology; Renal Function Testing. Am J Kideny Dis, 2006; Vol 47: 174-183.

  72. Jafar T, Schmid CH, Landa M, Giatras I, Toro R, Remuzzi G, et al. Angiotensin converting enzyme inhibitors and progression of nondiabetic renal disease: A meta analisis of patient level data. Ann Intern Med. 2001; 135: 73-87.

  73. 73 Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephrophathy due to type 2 diabetes. NEJM 2001; 345: 851-860

  74. Brenner BM, Cooper ME, deZeeuw D, Keane WF, Mitch WE, Parring HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. NEJM 2001; 345: 861-869.

  75. 75 Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. NEJM 2001; 345: 870-878.

  76. Carroll MF, Temte JL. Proteinuria in adults: a diagnostic approach. Am Fam Physician 2000; 62: 1333-1340.




2020     |     www.medigraphic.com